Home LiteratureArticle Details
PMID: 12164682 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens.

Journal of neuro-oncology ·Vol. 58 ·No. 2 ·2002-06-00 ·Pages 115-23

Haroun RI, Clatterbuck RE, Gibbons MC, Burger PC, Parker R, Fruehauf JP, Brem H

Abstract

Understanding chemoresistance profiles of brain tumors may aid in more educated selection of chemotherapeutic regimens for clinical trials and patient treatment. Although the literature contains many reports of the application of drug resistance assays, little is known about extreme drug resistance (EDR) in primary brain tumors. We undertook this study to determine chemoresistance profiles for brain tumors. From September 1991 to February 1998, we collected 64 brain tumor specimens from patients admitted to the Johns Hopkins Hospital. Tumors were classified according to the revised World Health Organization system. Brain tumor specimens were tested against 13 different chemotherapeutic agents using an extreme drug resistance assay. Results were reported as percent cell inhibition (PCI) (compared to control cultures). A drug resistance profile (extreme, intermediate, or low) was determined based on statistical comparison to a historical database of tumor specimens tested against the same panel of chemotherapeutic agents. Brain tumor specimens were classified histologically as Grade IV astrocytoma (glioblastoma multiforme, n = 35), Grade II/III astrocytoma (n = 11), oligodendroglioma (n = 6), meningioma (n = 9), hemangiopericytoma (n = 2), and ependymoma (n = 1). A large percentage of glioblastomas displayed extreme drug resistance to paclitaxel (69%, n = 35), SN38 (75%, n = 28), and vincristine (38%, n = 29). The majority of Grade II/III astrocytomas displayed extreme drug resistance to carboplatin (67%, n = 6), cisplatin (60%, n = 10), and paclitaxel (60%, n = 10). In a similar fashion, oligodendrogliomas displayed extreme drug resistance to vincristine (60%, n = 5) and paclitaxel (50% n = 6). Most meningiomas displayed extreme drug resistance to vincristine (75%, n = 8), dacarbazine (63%, n = 8), and 4-HC (50%, n = 8). Through the continued analysis of brain tumor specimens and compilation of data from multiple institutions, chemoresistance profiles could assist in the development of rationale clinical trials and treatment regimens for patients with brain tumors.

MeSH Terms
Brain Neoplasms/drug therapy,pathology Cell Division/drug effects Drug Resistance, Neoplasm Humans
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Haroun Raymond I
Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Clatterbuck Richard E
Gibbons M Christopher
Burger Peter C
Parker Ricardo
Fruehauf John P
Brem Henry
References (56)
56 references, click to expand
  1. Tumor chemosensitivity and chemoresistance assays.
    Cancer. 1997 Apr 1;79(7):1447-50 PMID: 9083168
  2. Intravenous carboplatin for recurrent malignant glioma: a phase II study.
    J Clin Oncol. 1991 May;9(5):860-4 PMID: 1849986
  3. Tumor chemosensitivity and chemoresistance assays.
    Cancer. 1996 Mar 15;77(6):1020-5 PMID: 8635118
  4. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
    J Neurosurg. 1997 May;86(5):840-4 PMID: 9126900
  5. Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.
    Cancer Chemother Pharmacol. 1990;26(4):263-8 PMID: 2369790
  6. The new WHO classification of brain tumours.
    Brain Pathol. 1993 Jul;3(3):255-68 PMID: 8293185
  7. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
    N Engl J Med. 1980 Dec 4;303(23):1323-9 PMID: 7001230
  8. Murine P-glycoprotein on stromal vessels mediates multidrug resistance in intracerebral human glioma xenografts.
    Br J Cancer. 1997;76(4):445-50 PMID: 9275020
  9. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.
    Cancer Treat Rep. 1983 Feb;67(2):121-32 PMID: 6337710
  10. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.
    Neurosurgery. 1997 Feb;40(2):271-5 PMID: 9007858
  11. Predictive tests for the response to cancer chemotherapy: limitations related to the prediction of rare events.
    Cancer Treat Rep. 1984 Apr;68(4):611-3 PMID: 6713417
  12. Platinum analogues in the treatment of recurrent high grade astrocytoma.
    Cancer Treat Rev. 1998 Oct;24(5):307-16 PMID: 9861194
  13. The blood-brain barrier efflux transporters as a detoxifying system for the brain.
    Adv Drug Deliv Rev. 1999 Apr 5;36(2-3):195-209 PMID: 10837716
  14. Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment.
    Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 PMID: 10598694
  15. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures.
    J Natl Cancer Inst. 1990 Apr 4;82(7):582-8 PMID: 2313735
  16. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study.
    Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 PMID: 9218294
  17. Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas.
    J Clin Oncol. 1997 Dec;15(12):3427-32 PMID: 9396393
  18. Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors.
    Cancer Res. 1985 Nov;45(11 Pt 1):5436-41 PMID: 4053017
  19. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium.
    J Clin Oncol. 1997 Sep;15(9):3121-8 PMID: 9294475
  20. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain.
    Cancer Res. 1993 Jan 15;53(2):329-33 PMID: 8417826
  21. Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in-vitro chemosensitivity of haematological malignancies.
    Leuk Res. 1986;10(4):445-9 PMID: 2421109
  22. Chemotherapy of malignant gliomas.
    Neurosurg Rev. 1984;7(1):3-12 PMID: 6379510
  23. The treatment of anaplastic oligodendrogliomas and mixed gliomas.
    Neurosurgery. 1993 Mar;32(3):365-70; discussion 371 PMID: 8455760
  24. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
    N Engl J Med. 2000 Nov 9;343(19):1350-4 PMID: 11070098
  25. Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay.
    Lancet. 1991 Mar 23;337(8743):711-4 PMID: 1672185
  26. The basis for current treatment recommendations for malignant gliomas.
    J Neurooncol. 1994;20(2):111-20 PMID: 7807189
  27. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.
    J Neurooncol. 1993 Jan;15(1):75-7 PMID: 8455065
  28. He's not going to talk about in vitro predictive assays again, is he?
    J Natl Cancer Inst. 1990 Jan 17;82(2):96-101 PMID: 2403594
  29. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
    J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 PMID: 9776413
  30. Clinical experience with vincristine (NSC-67574) in tumors of the central nervous system and other malignant diseases.
    Cancer Chemother Rep. 1968 Dec;52(7):733-41 PMID: 5743710
  31. Assumptions in the radiotherapy of glioblastoma.
    Neurology. 1980 Sep;30(9):907-11 PMID: 6252514
  32. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.
    J Neurosurg. 1978 Sep;49(3):333-43 PMID: 355604
  33. Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure.
    J Neurooncol. 1992 Feb;12(2):187-91 PMID: 1560266
  34. Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model.
    Anticancer Res. 1993 Sep-Oct;13(5C):1825-9 PMID: 8267387
  35. Predictive value of a single diagnostic test in unselected populations.
    N Engl J Med. 1966 May 26;274(21):1171-3 PMID: 5934954
  36. Successful chemotherapy for recurrent malignant oligodendroglioma.
    Ann Neurol. 1988 Apr;23(4):360-4 PMID: 3382171
  37. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
    J Neurosurg. 1997 May;86(5):845-52 PMID: 9126901
  38. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy.
    J Neurosurg. 1992 May;76(5):741-5 PMID: 1564535
  39. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors.
    J Clin Oncol. 1995 Aug;13(8):2066-71 PMID: 7636549
  40. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors.
    Cancer Treat Rep. 1980 Feb-Mar;64(2-3):237-44 PMID: 7407756
  41. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia.
    Cancer Lett. 1988 Aug 30;41(3):323-32 PMID: 3165705
  42. O6-alkylguanine-DNA alkyltransferase activity in human brain tumors.
    Cancer Lett. 1990 Dec 3;55(2):153-8 PMID: 2265415
  43. Chemotherapy for malignant gliomas.
    Baillieres Clin Neurol. 1996 Jun;5(2):371-93 PMID: 8781278
  44. Chemotherapy for meningiomas.
    J Neurooncol. 1996 Sep;29(3):269-72 PMID: 8858533
  45. CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer. Phase II study.
    Cancer. 1973 Jul;32(1):38-43 PMID: 4716783
  46. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas.
    J Neurooncol. 1994;19(1):69-74 PMID: 7815106
  47. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.
    N Engl J Med. 1978 Jun 15;298(24):1321-7 PMID: 77475
  48. The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
    JAMA. 1972 Oct 30;222(5):549-52 PMID: 4343318
  49. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.
    Cancer. 1993 Apr 15;71(8):2585-97 PMID: 8453582
  50. Primary bioassay of human tumor stem cells.
    Science. 1977 Jul 29;197(4302):461-3 PMID: 560061
  51. Initial clinical trials with methyl-CCNU 1-(2-chlorethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU).
    Cancer. 1973 May;31(5):1164-9 PMID: 4705154
  52. Phase II study of paclitaxel in patients with recurrent malignant glioma.
    J Clin Oncol. 1996 Aug;14(8):2316-21 PMID: 8708723
  53. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo.
    Science. 1990 Mar 23;247(4949 Pt 1):1457-61 PMID: 2108497
  54. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.
    J Clin Oncol. 1994 Oct;12(10):2013-21 PMID: 7931469
  55. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
    J Neurosurg. 1991 Mar;74(3):441-6 PMID: 1993909
  56. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.
    Lancet. 1995 Apr 22;345(8956):1008-12 PMID: 7723496
Article Info
Journal
Journal of neuro-oncology
Abbr.
J Neurooncol
ISSN
0167-594X
DOI
10.1023/a:1016049111941
Published
2002-06-00
Pages
115-23
Language
English
Region
United States
NLM ID
8309335
Subset
IM
Grants
NCI NIH HHS · CA-09574 · United States
NCI NIH HHS · U19 CA52857 · United States
External Links
PubMed source DOI: 10.1023/a:1016049111941 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2